Back to School: How biopharma can reboot drug development. Access exclusive analysis here

HIV tox trail to cancer

Researchers from the National Cancer Institute believe it may be possible to repurpose some approved HIV protease inhibitors to treat cancer, an idea inspired by the similar toxicity profiles of HIV protease inhibitors and inhibitors of a well-known cancer pathway.

Last

Read the full 406 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE